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Monocyte chemoattractant protein (MCP)-1, a 76-amino acid
protein, is a member of the C-C subfamily of chemokines. MCP-1
has been shown to cause monocyte and macrophage recruitment
during inflammation states (Grimm et al, 1996; Mazzucchelli et al,
1996). Furthermore, MCP-1 has been implicated in mediating
monocyte and tumour-associated macrophage (TAM) infiltration in
various solid tumours of epithelial origin (Leonard et al, 1990). The
role of TAM infiltration of malignant tumours is still controversial.
TAMs have been found to be cytotoxic to tumour cells when acti-
vated in vivo or in vitro (Fidler et al, 1984; Brunda et al, 1991).
However, TAMs constitute a heterogeneous population that may
have both inhibitory and stimulatory influences on malignant growth
(Peng et al, 1997). Mantovani et al (1994) reported that TAMs
promote tumorigenesis, angiogenesis and metastatic spread of malig-
nant tumours by producing various chemokines such as transforming
growth factor (TGF)-b, TNF-a, interleukin (IL)-1 and IL-6.
MCP-1 has been investigated in a wide variety of human malig-
nancies, e.g. malignant glioma, melanoma, bladder, prostate and
breast cancer (Graves et al, 1992; Kuratsu et al, 1993; Desbaillets
et al, 1994; Mazzucchelli et al, 1996; Amann et al, 1998; Valkovic
et al, 1998). Regarding ovarian cancer, Negus et al (1995) reported
that MCP-1, as produced by epithelial ovarian cancer cells,
contributes to the local accumulation of TAMs, consequently
influencing tumour behaviour. Furthermore, MCP-1 down-regula-
tion correlates with inhibition of monocyte migration within
ovarian cancer tissue (Negus et al, 1998). To the authors’ knowl-
edge no data on MCP-1 serum levels in ovarian cancer patients
have been reported to date.
The aim of this study was to evaluate whether MCP-1 serum
levels could serve as differentiation marker for ovarian cancer and
benign ovarian cysts, providing additional information to the
established tumour marker CA 125. A further aim of the study was
to investigate the prognostic potential of MCP-1 serum levels
regarding disease-free and overall survival. In this respect we
examined MCP-1 serum levels in healthy women and in patients
with benign cysts, primary ovarian cancer and recurrent ovarian
cancer.
MATERIALS AND METHODS
Patient characteristics
This retrospective study includes 86 serological examinations of
patients with ovarian cancer. Clinical data were obtained from files
at the University Hospital of Vienna, Department of Gynaecology
and Obstetrics. Forty-eight patients had primary ovarian cancer
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stages I (n = 8), II (n = 11) and III (n = 29). Median age at the time
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Summary The chemokine monocyte chemoattractant protein (MCP)-1 is an important mediator of monocyte infiltration in various solid
tumours of epithelial origin. The aim of the present study was to evaluate the role of MCP-1 in the natural history of ovarian cancer and to
determine its value as differentiation marker and prognostic marker regarding disease free and overall survival. This retrospective study
comprises 86 patients with ovarian cancer, 48 with primary ovarian cancer and 38 with recurrent ovarian cancer, 67 patients with benign
ovarian cysts and 42 healthy women. Median serum levels in patients with primary ovarian cancer, recurrent ovarian cancer, benign ovarian
cysts and in healthy women were 535.6 (range 129.6–1200) pg ml–1, 427.3 (range 193.4–1101) pg ml–1, 371.2 (range 222–986.8) pg ml–1 and
318.7 (range 241.3–681.4) pg ml–1 respectively (Mann–Whitney U-test,  P < 0.001). Univariate logistic regression models revealed a
significant influence of MCP-1 serum levels on the odds of presenting with primary ovarian cancer versus benign cysts and versus healthy
women respectively (univariate logistic regression, P < 0.001 and P < 0.001 respectively). In a multivariate logistic regression model
considering MCP-1 and CA 125 serum levels simultaneously, both MCP-1 and CA 125 revealed statistical significance on the odds of
presenting with primary ovarian cancer versus benign cysts (multivariate logistic regression, P = 0.05 and P < 0.001 respectively). In ovarian
cancer patients, MCP-1 serum levels showed a statistically significant correlation with histological grade (Mann–Whitney U-test, P = 0.02) and
age at the time of diagnosis (Mann–Whitney U-test, P = 0.03). Elevated MCP-1 serum levels prior to therapy were not associated with
disease-free and overall survival (log-rank test, P = 0.2 and P = 0.7 respectively). In summary these data indicate that MCP-1 might play a
functional role in the natural history of ovarian cancer and might serve as differentiation marker between benign ovarian cysts and ovarian
cancer, providing additional information to the established tumour marker CA 125.
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Correspondence to: L Heflerof diagnosis was 59 (range 29–87) years. Histologically, 21
tumours were typed as serous adenocarcinoma, 14 as mucinous
adenocarcinoma, 7 as undifferentiated carcinoma, 3 as clear cell
carcinoma and three as endometrioid ovarian cancer. Thirty-eight
patients had recurrent ovarian cancer.
Additionally, we investigated MCP-1 serum levels in 67
patients with benign cysts. Serous and mucinous cystadenomas
were found in 45 and 22 cases respectively. Furthermore, MCP-1
serum levels were evaluated in a panel of 42 healthy women. CA
125 levels were evaluated in all patients with primary ovarian
cancer and benign cysts.
Clinical management
Patients with primary ovarian cancer underwent hysterectomy,
bilateral salpingo-oophorectomy, pelvic and para-aortic lymph-
adenectomy, and omentectomy. Patients with tumour stages Ic–III
and patients with clear cell carcinoma received a platinum and/or
paclitaxel containing chemotherapy regimen. Patients with recur-
rent ovarian cancer received cytoreductive surgery and/or a
salvage chemotherapy regimen. Histological grading was carried
out according to International Union Against Cancer criteria. The
stage of disease was classified according to FIGO. All patients
were followed up in 3-month intervals including vagino-rectal
palpation, abdominal ultrasound examination and serum tumour
marker evaluation. In cases of clinically doubtful findings and/or
tumour marker elevation computerized tomography was
performed. For the aim of this study, all histological specimens
were reviewed by an experienced pathologist, blinded to the clin-
ical data.
Serum assay
Patients’ blood was obtained 24–48 h before surgery or at the time
of diagnosis of recurrent ovarian cancer by peripheral venous
puncture and was immediately centrifuged at 3000 g for 15 min.
The serum was frozen at –80°C until examination. For the
measurement of serum MCP-1 a commercially available enzyme-
linked immunosorbent assay was used (QuantikineTM Human
MCP-1 Immunoassay; R&D Systems, Minneapolis, MN, USA).
All serum MCP-1 analyses were performed at the same time, in
the same batch, and in duplicate according to manufacturer’s
instructions. The intra- and inter-assay variability was 4.9% and
5.8% respectively.
Statistical analysis
Due to the skewed distribution of MCP-1 serum values, median
and range of MCP-1 serum levels are given. Comparisons between
unpaired groups were made using the Mann–Whitney U-test.
Survival probabilities were calculated by the product limit method
of Kaplan and Meier. Differences between groups were tested
using the log-rank test. Spearman correlation coefficients of CA
125 and MCP-1 values were calculated for primary ovarian cancer
and benign cysts separately. CA 125 and MCP-1 values were log2-
transformed for further analysis. Logistic regression models were
used to analyse the influence of MCP-1 and CA 125 serum levels
on the probability for the presence of primary ovarian cancer
versus benign cysts. The univariate models show the influence of
each of the two variables on the probability for primary cancer
without considering the other one. Sensitivity and specificity were
calculated for each possible threshold value of estimated proba-
bility for primary ovarian cancer versus benign cysts. Based on
these values Receiver Operator Characteristics (ROC) curves were
constructed to visualize the relationship between MCP-1 and CA
125, respectively, and primary ovarian cancer. Considering CA
125 and MCP-1 simultaneously, multivariate logistic regression
analysis was used to compare patients with primary ovarian cancer
and benign ovarian cysts. Based on this analysis, a third ROC
curve was constructed to show the diagnostic power of their simul-
taneous consideration. A further univariate logistic regression
model was used to analyse the influence of MCP-1 serum levels
on the probability for the presence of primary ovarian cancer
versus healthy women. Ninety-five per cent confidence intervals
(CI) for odds ratios (ORs) were calculated using the profile likeli-
hood method. Odds ratios refer to a unit increase on the log2-scale,
i.e. a doubling on the original scale. P-values of ≤ 0.05 were
considered statistically significant. We used the SAS statistical
software system (SAS Institute Inc., Cary, NC, USA) to do the
calculations.
Medical databases MEDLINE since 1966 and EMBASE since
1989 were searched to identify reports on MCP-1 serum concen-
trations in ovarian cancer patients.
RESULTS
MCP-1 serum levels in patients with primary ovarian
cancer, recurrent ovarian cancer, benign ovarian cysts
and healthy women
The overall median MCP-1 serum level was 398.3 (range
129.6–1200) pg ml–1. Median MCP-1 serum levels in patients
with primary ovarian cancer, recurrent ovarian cancer, benign
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Figure 1 Box plot of MCP-1 serum levels (pg ml–1) in patients with primary
ovarian cancer (n = 48; A), recurrent ovarian cancer (n = 38; B), benign
ovarian cysts (n = 67; C), and healthy women (n = 45; D). Horizontal lines in
the box represent the 1st, 2nd (the median), and 3rd quartile; whiskers
(vertical lines) represent extension of data up and down, l represents
outside valuesovarian cysts and healthy women were 535.6 (range 129.6–
1200) pg ml–1, 427.3 (range 193.4–1101) pg ml–1, 371.2 (range
222–986.8) pg ml–1 and 318.7 (range 241.3–681.4) pg ml–1 respec-
tively. A box plot of MCP-1 serum levels is shown in Figure 1.
MCP-1 serum levels did not correlate with CA 125 serum levels in
patients with primary ovarian cancer patients (Spearman correla-
tion coefficient, P = 0.12) and in patients with benign ovarian cysts
(Spearman correlation coefficient, P = 0.09).
MCP-1 serum levels and the presence of primary
ovarian cancer and recurrent ovarian cancer compared
with healthy women
MCP-1 serum levels were significantly higher in patients with
primary ovarian cancer compared with patients with recurrent
ovarian cancer (Mann–Whitney U-test, P = 0.02). Patients with
primary and recurrent ovarian cancer showed significantly higher
MCP-1 serum levels than healthy women (Mann–Whitney U-test,
P < 0.001 and P < 0.001 respectively). In a univariate logistic
regression model, MCP-1 serum levels had a significant influence
on the odds of presenting with primary ovarian cancer versus
healthy women (univariate logistic regression, P < 0.001) with an
OR of 7.9 (95% CI 3.1–24.1).
MCP-1 serum levels and the presence of primary
ovarian cancer compared with benign cysts
Median MCP-1 serum levels in patients with primary ovarian
cancer and benign ovarian cysts were 535.6 (range 129.6–
1200) pg mL–1 and 371.2 (range 222–986.8) pg ml–1 respectively
(Mann–Whitney U-test, P < 0.001). Median CA 125 serum levels
in patients with primary ovarian cancer and benign ovarian cysts
were 851 (range 13.7–19 619) U ml–1 and 15.7 (range 3.1–
1340) U ml–1, respectively (Mann–Whitney U-test, P < 0.001).
Univariate logistic regression models revealed that MCP-1 and CA
125 serum levels had a significant influence on the odds of
presenting with primary ovarian cancer versus benign cysts
(univariate logistic regression, P < 0.001 and P < 0.001 respec-
tively) with ORs of 4.9 (95% CI, 2.3–11.9) and 2.5 (95% CI
1.9–3.6) respectively. At 640 pg ml–1 MCP-1 achieved a sensitivity
of 31.3% and a specificity of 95%. At 194 U ml–1, CA 125
achieved a sensitivity of 65% and a specificity of 95%.
In a multivariate regression model considering serum MCP-1
and CA 125 simultaneously, both MCP-1 and CA 125 revealed a
significant influence on the odds of presenting with primary
ovarian cancer versus benign cysts (multivariate logistic regres-
sion, P < 0.05 and P < 0.001 respectively). MCP-1 and CA 125
achieved a sensitivity of 75% and a specificity of 95%. ROC
curves of MCP-1, CA 125 and the combination of both markers
are shown in Figure 2.
Correlation of MCP-1 serum levels in primary ovarian
cancer with tumour stage, lymph node involvement,
histological grade and age at the time of diagnosis
When MCP-1 serum levels, taken prior to therapy, were grouped
by tumour stage, lymph node involvement, histological grade and
age at the time of diagnosis we found a statistically significant
correlation with histological grade (357.4 pg ml–1 vs 584 pg ml–1
for G1 vs G2, G3; Mann–Whitney U-test, P = 0.02) and age at
the time of diagnosis (430.4 pg ml–1 vs 582.8 pg ml–1 for age
< 50 years vs age > 50 years; Mann–Whitney U-test, P = 0.03).
The other investigated parameters showed no significant correla-
tion with MCP-1 serum levels.
Preoperative MCP-1 serum levels as prognostic factors
in ovarian cancer
MCP-1 lacks a clearly defined cut-off value. Due to the skewed
distribution of MCP-1 serum levels a cut-off value of 718 pg ml–1
was selected according to the 75th quantile of serum concentra-
tions measured in the panel of primary ovarian cancer patients.
Elevated preoperative MCP-1 serum levels were not associated
with disease-free and overall survival (log-rank-test P = 0.2 and
log-rank-test, P = 0.7 respectively).
DISCUSSION
Chemokines form a superfamily of small, inducible, pro-inflam-
matory chemotactic cytokines. These proteins have been reported
to be involved in a variety of immune and inflammatory responses,
acting primarily as chemoattractants and activators of specific
leucocytes. MCP-1 is a member of the C-C subfamily of
chemokines and is expressed upon stimulation in a wide variety of
cells, such as mononuclear leucocytes, fibroblasts, endothelial and
epithelial cells, smooth muscle cells, melanocytes and various
tumour cells (Schall, 1991). MCP-1 is a key element of the
immunological response to malignant growth, mainly via attrac-
tion and activation of TAMs (Leonard and Yoshimura, 1990).
Our data show that patients with primary and recurrent ovarian
cancer have significantly higher MCP-1 serum levels compared
with patients with benign ovarian cysts and healthy women. In our
series, MCP-1 had a significant influence on the odds of presenting
with ovarian malignancy. This indicates that MCP-1 might be
MCP-1 in ovarian cancer 857
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Figure 2 Receiver operator characteristics (ROC) curves comparing
patients with primary ovarian cancer (n = 48) and benign ovarian cysts
(n = 67) with respect to their MCP-1 serum levels (...), CA 125 serum levels
(nnn) and to a simultaneous consideration of both variables (–)selectively up-regulated after malignant transformation. MCP-1
seems to play a functional role in the natural history of ovarian
cancer, possibly by mediating TAM infiltration of malignant
tissue, however, the potential mechanisms involved remain to be
elucitated.
Regarding the differentiation between benign and malignant
growth, MCP-1 has been investigated in malignant and benign
gliomas by Kuratsu et al (1993). They reported that elevated MCP-
1 levels in cerebrospinal fluids were indicative of the presence of
malignant versus benign glioma. Furthermore, in patients with
malignant gliomas, MCP-1 serum levels were associated with
subarachnoid dissemination of disease. With respect to these
results it has been speculated that MCP-1 might be clinically
useful establishing a diagnosis of malignant glioma and in
detecting subarachnoidal tumour spread (Kuratsu et al, 1993).
With respect to differential diagnosis of benign and malignant
adnexal masses, our data showed that MCP-1 serum levels were
elevated in patients with ovarian cancer compared with patients
with benign ovarian cysts. The higher the MCP-1 serum levels, the
higher were the odds of presenting with primary ovarian cancer in
our series. A multivariate logistic regression model showed that
MCP-1 revealed diagnostic information independent from the
established tumour marker CA 125. This documents the fact that
MCP-1 is a possible candidate in ongoing efforts to find adequate
combined screening systems, e.g. by combining CA 125 with
transvaginal ultrasound examination or Doppler ultrasound
examination.
The correlation of MCP-1 and histopathological parameters has
been investigated in various malignancies. Valkovic et al (1998)
reported an association between MCP-1 expression and histolog-
ical grade in invasive ductal breast cancer. Furthermore, Amann et
al (1998) showed that urine MCP-1 levels correlate with histolog-
ical grade, and distant metastasis in bladder cancer. In accordance
with these studies we found lower MCP-1 serum levels in patients
with G1 tumours compared with G2 and G3 tumours, whereas
MCP-1 serum levels were not associated with tumour stage and
lymph node involvement. These findings indicate that MCP-1
serum levels in ovarian cancer are not reflective of the tumour
bulk, but rather indicative of strongly proliferating tumours.
Consequently, it could be speculated that dedifferentiation of
tumour cells provokes a more aggressive host immune response
(Negus et al, 1995).
In our study MCP-1 serum levels of patients with primary
ovarian cancer and recurrent ovarian cancer were markedly
elevated compared with patients harbouring benign ovarian cysts
and healthy women. These results are in accordance with experi-
mental data pointing to the involvement of MCP-1 in immunolog-
ical host defence reactions in ovarian cancer patients (Melani et al,
1995). Additionally, we found a statistically significant difference
between primary and recurrent ovarian cancer. Hence, it can be
hypothesized that human MCP-1 secretion and host immune
response versus malignant growth decreases in the clinical course
of ovarian cancer. A decline in immunological competence might
be one reason for the worse prognosis of patients with recurrent
ovarian cancer compared with patients with primary ovarian
cancer (Berek, 1994).
No data have been published so far regarding the prognostic
value of MCP-1 serum levels in ovarian cancer. Chen et al (1984)
demonstrated that leucocytic infiltration of ovarian cancer tissue is
correlated with a favourable prognosis regarding overall survival.
Furthermore, Haskill et al (1982) reported that in ovarian cancer
patients tumour infiltration by lymphocytes and macrophages is
positively associated with response to adjuvant chemotherapy.
However, it has also been reported that monocyte/macrophage
infiltration of malignant tissue may promote tumour growth by
producing various chemokines, e.g. TGF-b, TNF-a, IL-1 and IL-6
(Mantovani et al, 1994; Negus et al, 1995). In our series, MCP-1
serum levels showed no influence on the patients’ prognosis
regarding disease-free and overall survival.
In summary, our data indicate that MCP-1 might play a func-
tional role in the natural history of ovarian cancer, possibly by
mediating host defence reactions, such as TAM infiltration of
tumour tissue. Furthermore, MCP-1 is a discriminator between
benign adnexal masses and ovarian cancer, providing additional
information to CA 125. Further studies are warranted to determine
the possible clinical value of MCP-1 in the differential diagnosis
of adnexal masses.
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